Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients
Background: Carfilzomib improves the prognosis of multiple myeloma (MM) patients but significantly increases cardiovascular toxicity. The timing and effect of Carfilzomib therapy on the left ventricular function is still under investigation. We sought to assess the echocardiographic systo-diastolic...
Main Authors: | Giulia Mingrone, Anna Astarita, Lorenzo Airale, Ilaria Maffei, Marco Cesareo, Teresa Crea, Giulia Bruno, Dario Leone, Eleonora Avenatti, Cinzia Catarinella, Marco Salvini, Giusy Cetani, Francesca Gay, Sara Bringhen, Franco Veglio, Fabrizio Vallelonga, Alberto Milan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.645678/full |
Similar Items
-
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction
by: Anna Astarita, et al.
Published: (2021-04-01) -
Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy
by: Giulia Bruno, et al.
Published: (2019-05-01) -
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
by: Anna Astarita, et al.
Published: (2023-02-01) -
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience
by: Giulia Mingrone, et al.
Published: (2023-02-01) -
Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)